AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Alzex Neuropharma Inc.

$0 +$0.00 (+100.00%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0
Year Range
$0$0.07
Market Cap
602
AVG Volume
10
Trailing/Forward PE
-0/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Net Income (USD)
-100K-75K-50K-25K021 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Net Income (USD) by quarter
PeriodNet Income (USD)
24 Q2-85.58K
23 Q3-43.33K
23 Q2-43.42K
23 Q1-81.8K
22 Q4-43K
22 Q3-54.12K
22 Q2-34.9K
22 Q1-34.03K
21 Q3-20.62K
21 Q2-1.5K
Operating Income (USD)
-100K-75K-50K-25K021 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Operating Income (USD) by quarter
PeriodOperating Income (USD)
24 Q2-83.68K
23 Q3-41.51K
23 Q2-41.63K
23 Q1-80.03K
22 Q4-43K
22 Q3-52.64K
22 Q2-34.9K
22 Q1-34.03K
21 Q3-20.62K
21 Q2-1.5K
EBITDA (USD)
-100K-75K-50K-25K025K21 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI EBITDA (USD) by quarter
PeriodEBITDA (USD)
24 Q2-83.68K
23 Q3-41.51K
23 Q2-41.63K
23 Q1-80.03K
22 Q411.88K
22 Q3-52.64K
22 Q2-34.9K
22 Q1-34.03K
21 Q3-20.62K
21 Q2-1.5K
Cash Flows (USD)
-60K-40K-20K013 Q213 Q322 Q222 Q323 Q123 Q223 Q3
TRRI Cash Flows (USD) by quarter
PeriodCash Flows (USD)
23 Q3-3.59K
23 Q2-1.79K
23 Q1-3.68K
22 Q3-28.88K
22 Q2-59.29K
13 Q3-9.83K
13 Q2-45.09K
EPS (USD)
-0.06-0.04-0.02021 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI EPS (USD) by quarter
PeriodEPS (USD)
24 Q2-0.06
23 Q3-0.03
23 Q2-0.03
23 Q1-0.05
22 Q4-0.03
22 Q3-0.04
22 Q2-0.02
22 Q1-0.02
21 Q3-0.01
21 Q2-0
Expenses (USD)
025K50K75K100K21 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Expenses (USD) by quarter
PeriodExpenses (USD)
24 Q283.68K
23 Q341.51K
23 Q241.63K
23 Q180.03K
22 Q443K
22 Q352.63K
22 Q234.9K
22 Q134.03K
21 Q320.62K
21 Q21.5K
Cash & Debt (USD)
050K100K150KCashLong Term DebtShort Term Debt21 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
24 Q2160
23 Q340
23 Q240
23 Q140
22 Q41.02K
22 Q31.02K
22 Q21.9K
22 Q1189
21 Q339
21 Q239
Debt ratios
-4-3-2-10121 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Debt ratios by quarter
PeriodDebt ratios
24 Q2-0.47
23 Q3-0.66
23 Q2-0.6
23 Q1-0.61
22 Q4-0.82
22 Q3-0.63
22 Q2-0.66
22 Q10
21 Q3-1.85
21 Q2-3
Return on Capital
0%10%20%30%40%21 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Return on Capital by quarter
PeriodReturn on Capital
24 Q215.29%
23 Q311.2%
23 Q212.65%
23 Q127.28%
22 Q419.72%
22 Q331.18%
22 Q228.53%
22 Q139.24%
21 Q320.98%
21 Q21.93%
Shares Outstanding
0500K1M1.5M2M21 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Shares Outstanding by quarter
PeriodShares Outstanding
24 Q21.51M
23 Q31.51M
23 Q21.51M
23 Q11.51M
22 Q41.51M
22 Q31.51M
22 Q21.51M
22 Q11.51M
21 Q31.51M
21 Q21.51M
Book Value Per Share (USD)
-0.4-0.3-0.2-0.1-021 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
24 Q2-0.37
23 Q3-0.26
23 Q2-0.23
23 Q1-0.2
22 Q4-0.14
22 Q3-0.12
22 Q2-0.08
22 Q1-0.06
21 Q3-0.07
21 Q2-0.05
Total Assets (USD)
05K10K15K20K21 Q221 Q322 Q122 Q222 Q322 Q423 Q123 Q223 Q324 Q2
TRRI Total Assets (USD) by quarter
PeriodTotal Assets (USD)
24 Q27.84K
23 Q36.22K
23 Q27.59K
23 Q18.97K
22 Q419.62K
22 Q319.62K
22 Q21.9K
22 Q1189
21 Q339
21 Q239
Alzex Neuropharma Inc.
TRRI
Stockpicker

Video analysis: TRRI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.